Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $10.6 million.

  • GeneDx Holdings' Share-based Compensation rose 19114.41% to $10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.2 million, marking a year-over-year increase of 36881.62%. This contributed to the annual value of $9.1 million for FY2024, which is 290306.75% up from last year.
  • As of Q3 2025, GeneDx Holdings' Share-based Compensation stood at $10.6 million, which was up 19114.41% from $7.8 million recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Share-based Compensation ranged from a high of $165.0 million in Q1 2021 and a low of -$912000.0 during Q4 2023
  • For the 5-year period, GeneDx Holdings' Share-based Compensation averaged around $15.4 million, with its median value being $3.1 million (2024).
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 447784.2% in 2022, then tumbled by 103958.33% in 2024.
  • Quarter analysis of 5 years shows GeneDx Holdings' Share-based Compensation stood at $37.0 million in 2021, then tumbled by 98.86% to $422000.0 in 2022, then tumbled by 316.11% to -$912000.0 in 2023, then surged by 411.95% to $2.8 million in 2024, then surged by 272.09% to $10.6 million in 2025.
  • Its Share-based Compensation was $10.6 million in Q3 2025, compared to $7.8 million in Q2 2025 and $4.0 million in Q1 2025.